Progenics Pharmaceuticals Inc

Progenics Pharmaceuticals — Investor Presentation (January 2018)

31 slides from Progenics Pharmaceuticals's investor presentation, Jan 8, 2018

  1. Slide 1: Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer

    Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer +, Si C . Exhibit 99.1 FIND FIGHT AND FOLLOW™ Progenics

  2. Slide 2: Disclosure Notice

    DISCLOSURE NOTICE This presentation may contain projections and other forward-looking statements regarding future events. Such statements are predictions only, and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties inc

  3. Slide 3: Our Mission

    OUR MISSION FIND FIGHT AND FOLLOW™ Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer AZEDRA® for Ultra Orphan NETs Near-term commercial opportunity; PDUFA Target Action Date of April 30, 2018 PSMA-Targeted Portfolio for Prostate Cancer Imaging agents and therapeutics de

  4. Slide 4: Pipeline

    PIPELINE Sa ED=D> Dx ULTRA-ORPHAN THERANOSTIC AZEDRA® Theranostic Pheochromocytoma & Paraganglioma PDUFA: April PROSTATE CANCER THERANOSTICS 1404 PSMA-targeted SPECT Imaging Agent PyL PsMActargeted PET Imaging Agent 1095 ‘Small Molecule Therapeutic PSMA-TTC ‘Thorium Conjugate Therapeutic DIGITAL TEC

  5. Slide 5: AZEDRA (iobenguane I 131)

    % }- +4 AZEDRA’ (iobenguane | 131) > Progenics FIND FIGHT AND FOLLOW™ ae

  6. Slide 6: AZEDRA (iobenguane I 131)

    AZEDRA’ (iobenguane | 131) * Selectively targets pheochromocytoma and paraganglioma (Pheo/Para) via the norepinephrine transporter? * Provides powerful and sustained tumor ablation over time * Contains over 99% active, therapeutic |-131 MIBGt * Orphan Drug Designation, Fast Track Status, Breakthroug

  7. Slide 7: Pheochromocytoma and Paraganglioma

    PHEOCHROMOCYTOMA AND PARAGANGLIOMA * Rare tumors found primarily in the adrenal glands Results in the release of excess hormones that control heart rate, metabolism and blood pressure Left untreated, tumors most often lead PARA to death due to metastatic disease, high blood pressure, heart failure,

  8. Slide 8: Pheochromocytoma and Paraganglioma

    PHEOCHROMOCYTOMA AND PARAGANGLIOMA Annual incidence: 2 to 8 per million in the US 15%-35% 16% ; of cases are metastatic/malignant Of cases suitable for surgery and not eligible recur after initial surgery? T for surgery?? i 4 i ! ' Tumor progression is Usually 5-15 years after initial the leading ca

  9. Slide 9: AZEDRA: Positive Data from Registrational Trial

    AZEDRA’*: POSITIVE DATA FROM REGISTRATIONAL TRIAL «et certer study undersea agreement with FDA + 68 evaluable patents Achieved Primary Favorable Tumor Meaningful Impact Safe & Generally Endpoint Response Data on Overall Survival Well Tolerated + 17 patients reported * 92.2% of patients * Data sugges

  10. Slide 10: AZEDRA: Trial Achieved Primary Endpoint

    AZEDRA: TRIAL ACHIEVED PRIMARY ENDPOINT Met the primary endpoint evaluating the proportion of patients who achieved a >50% reduction of all antihypertensive medication for at least six months. Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confiden

  11. Slide 11: AZEDRA: Favorable Tumor Response Rates

    AZEDRA: FAVORABLE TUMOR RESPONSE RATES Key secondary endpoint: the proportion of patients with overall tumor response as measured by RECIST 92.2% of evaluable patients (59/64) who received at least one AZEDRA therapeutic dose achieved partial response or stable disease Proportion of study patients w

  12. Slide 12: AZEDRA: U.S. Market Accessible with Small, Dedicated Salesforce

    AZEDRA: U.S. MARKET ACCESSIBLE WITH SMALL, DEDICATED SALESFORCE AZEDRA Initial Sales Territories * Guidelines recommend referral to multi-disciplinary centers with specialized resources * Majority of patients are treated at 20-25 centers, many of which are sites that are participating in our registr

  13. Slide 13: AZEDRA: Approval and Launch Readiness

    AZEDRA: APPROVAL AND LAUNCH READINESS Extensive market iw research on Pheo/Para with physicians, patients and caregivers Brand development, . poe Disease awareness positioning and ‘ campaign message research Payer market research of iw value proposition associated with target product pr underway for

  14. Slide 14: AZEDRA: Market Research Insights

    AZEDRA: MARKET RESEARCH INSIGHTS * — Recognize the clinical , Identify metastatic/ malignant Pheo/Para as an utility of AZEDRA fromthe | area of high unmet need with two overarching efficacy/safety profile goals of treatment: demonstrated in a heavily | * Reducing symptoms—symptoms related to pre-tr

  15. Slide 15: AZEDRA — Preparing for Commercialization

    AZEDRA — PREPARING FOR COMMERCIALIZATION Commercial Launch ..» AZEDRA Service Connection— Patient and HCP services hub ———— e Establish meaningful value proposition and engage payers Build Marketing, Access and Sales team -e Identify and profile Centers of Excellence * AZEDRA - Differentiated and co

  16. Slide 16: Disease Awareness Campaign Launched

    DISEASE AWARENESS CAMPAIGN LAUNCHED Jere to Listen, Here to. Patient Conferences HCP + Patient Website: KnowPheoPara.health HCP Conferences Speaker Deck

  17. Slide 17: AZEDRA Summary

    AZEDRA® SUMMARY REGULATORY: Exceeded primary end point under special protocol assessment (SPA) PDUFA: April 30, 2018 Orphan Drug designation, Fast Track, Breakthrough Therapy designation, Priority Review No FDA approved therapies, ultra-orphan population that can be targeted with small commercial ef

  18. Slide 18: PSMA Targeted Pipeline

    % }- +4 PSMA TARGETED PIPELINE ) FIND FIGHT AND FOLLOW™ Progenics

  19. Slide 19: Addressing Prostate Cancer with a Novel Portfolio of PSMA Targeted Diagnostics and Therapeutics

    ADDRESSING PROSTATE CANCER WITH A NOVEL PORTFOLIO OF PSMA TARGETED DIAGNOSTICS AND THERAPEUTICS PSMA CADx Diagnose Treat Monitor Technetium-99m labeled small molecule PSMA-targeted SPECT/CT imaging agent to diagnose and detect localized prostate cancer as well as soft tissue and bone metastases Phas

  20. Slide 20: 1404 PSMA-Targeted Imaging Agent

    1404 PSMA-TARGETED IMAGING AGENT * SPECT/CT radiopharmaceutical product candidate targeting PSMA * Phase 3 enrollment complete; data expected 3Q18 * Potential to transform clinical practice with improved detection & monitoring * Initial application: enabling Active Surveillance Gleason 4+5 Lesion SP

  21. Slide 21: 1404 Phase 3 Study Design

    1404 PHASE 3 STUDY DESIGN ~450 Biopsy Confirmed Low Grade PC (Gleason Score <3+4) patients SPECT/ CT Prostatectomy Histopathology who are candidates for Imaging or biopsy Active Surveillance Primary Specificity of 1404 to identify patients without clinically significant prostate cancer Endpoint Sens

  22. Slide 22: PyL Imaging Characteristics

    Enables visualization of both bone and soft tissue metastases Highly specific to prostate cancer cells, not confounded by degenerative or inflammatory conditions Very high standardized uptake values (SUV) even in small lesions Identified more lesions than conventional imaging Could detect lesions as

  23. Slide 23: PyL Clinical Development Program to Support NDA

    PyL CLINICAL DEVELOPMENT PROGRAM TO SUPPORT NDA Indication: PET/CT imaging agent to determine the presence or absence of recurrent and/or metastatic prostate cancer Patient Population Primary End Truth standardto be used Secondary Endpoints Study Status ‘Study 1: PyL Phase 2/3 Trial High risk locali

  24. Slide 24: 1095: PSMA Targeted Small Molecule Theranostic for Prostate Cancer

    24 1095: PSMA TARGETED SMALL MOLECULE THERANOSTIC FOR PROSTATE CANCER * Best PSA Response in 25 patients 25 5 10 15 20 PATIENT NUMBER Zechmann et al. Eur J Nuc! Med Mol Imaging, 2014 100 * Targeted small molecule radiotherapeuticthat selectively binds to PSMA * Markedly reduced PSA levelsina heavily

  25. Slide 25: 1095 Phase 2 Study Design

    1095 PHASE 1 STUDY DESIGN: Open Label, Dose Escalating, Safety & Efficacy Study 1095 Study Overview: Treatment Screening Treatment Phase unas Fats 2 Follow u| Patients Safety P Dosimetry, Escalation Efficacy Safety Patient Subjects with metastatic castration-resistant prostate cancer (mCRPC) Populat

  26. Slide 26: PSMA-Targeted Thorium Conjugate (PSMA-TTC)

    PSMA-TARGETED THORIUM CONJUGATE(PSMA-TTC) Partnered with Bayer 2 6 en) * Ina prostate cancer mouse model, PSMA-TTC proved efficacious to suppress tumor growth and bone degradation! * Phase 1 in patients with mCRPC plannedto commence in 2018 * Potential added effect on bone metastases due to decay pr

  27. Slide 27: Pioneer PSMA CADx

    PIONEER PSMA CADx™ PSMA imaging significantly better in PSMA imaging study found a high impact on identifying aggressive tumor in prostate. management intent, with a planned Zamboglou, C. et al, EINMMI 2016 management change in 51% of patients. Roach, PJ. et al, JNM 2017 A patient centric approach t

  28. Slide 28: Corporate Overview

    % }- +4 CORPORATE OVERVIEW > Progenics FIND FIGHTAND FOLLOW™

  29. Slide 29: Financial Overview

    FINANCIAL OVERVIEW 3Q17 Financial Snapshot * $98.3M cash as of 9/30/17 * Quarterly Revenues: $2.7M * Net loss: $0.22 per share * 70.3M shares outstanding Strong financial position to advance portfolio and launch AZEDRA 2 FIND FIGHTAND FOLLOW™ RELISTOR® franchise provides financial foundation: * Mark

  30. Slide 30: 2018 Program Goals

    LEADING DEVELOPMENT OF TARGETED RADIOPHARMACEUTICALS TO DETECT AND TREAT CANCER 2018 Program Goals PDUFA: April 30 AZEDRA® READY TO LAUNCH AT APPROVAL 1404 PyL PSMA-TTC 30 FIND FIGHTAND FOLLOW™

  31. Slide 31: Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer

    Leading Development of Targeted Radiopharmaceuticals to Detect and Treat Cancer ~s, Si C . FIND FIGHTAND FOLLOW™ Proge! nics

Progenics Pharmaceuticals — Investor Presentation (January 2018) on 6ix